ClinicalTrials.gg
RecruitingNCT07190079ECTPEDUpdated Oct 2, 2025

Saline Contrast Electrical Impedance Tomography Method for Diagnosis of Acute Pulmonary Embolism

An observational study in Acute Pulmonary Embolism, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-02.

Sponsored by Peking Union Medical College Hospital · Observational

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
343
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 72 studies in Pulmonary Embolism with a site in China — 26 open to participants now, 31 under way, 1 of them phase 3. Pulmonary Embolism · China.

Planned enrollment
29th of 39
343 · median 1,000
Started
2025
with 5 others
Observational
39 of 72
20 open now
Primary completion
2027-05
later than 19 of 30 live
Registered
65th of 72
by date
Lead sponsor
6 of 72
Peking Union Medical College Hospital

Among the 72 studies in Pulmonary Embolism with a site in China, this one is the 29th largest by planned enrollment of the 39 observational ones that give a count, is one of 6 that started in 2025, is one of 39 observational ones, reaches primary completion later than 19 of the 30 other live ones, and was the 65th registered.

Pulmonary Embolism

833 studies on the registry are indexed under Pulmonary Embolism; 172 are open to participants now.

Browse Pulmonary Embolism studies →

Open to participants now

26 of the 72 studies in Pulmonary Embolism with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 130 Pulmonary Embolism studies recruiting now, 110 (85%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Pulmonary Embolism with a site in China, or all of them as a file.
02

Study summary

The goal of this observational study is to compare the consistency of saline contrast Electrical Impedance Tomography(EIT) method and Computed Tomography Pulmonary Angiography (CTPA) in diagnosing acute pulmonary embolism. The main question it aims to answer is:

Can bedside saline contrast EIT method be used for the diagnosis of acute pulmonary embolism? The participants will undergo saline contrast EIT and CTPA examinations successively within 24 hours.

03

Conditions studied

  • Acute Pulmonary Embolism

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with clinically suspected or confirmed acute pulmonary embolism (PE) presenting with acute respiratory failure.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with clinically suspected or confirmed acute pulmonary embolism (PE) presenting with acute respiratory failure;
  2. Availability of CTPA results within 24 hours or scheduled to undergo CTPA within the next 24 hours;
  3. Age >18 years; no gender restrictions;
  4. Presence of central venous access (internal jugular or subclavian vein) or peripheral forearm venous access;
  5. Willingness to participate with signed from either the patient or legal guardian.

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy or lactation;
  2. Relative to EIT examination (e.g., chest wall wounds at electrode belt placement site, presence of pacemakers);
  3. Severe hypernatremia (serum sodium >155 mmol/L);
  4. Inability to maintain expiratory breath-hold for ≥8 seconds;
  5. >50 or severe thoracic deformities;
  6. Current extracorporeal membrane oxygenation (ECMO) therapy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
343 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients clinically suspected with acute PE

    This study will enroll adult patients (\>18 years) with clinically suspected or confirmed acute pulmonary embolism (PE) presenting with acute respiratory failure, who either undergo computed tomography pulmonary angiography (CTPA) within 24 hours or are scheduled for CTPA within the next 24 hours. Eligible participants need to have an indwelling central venous catheter (internal jugular or subclavian vein) or a peripheral forearm venous line, with no restrictions on gender.

    Diagnostic Test: Saline contrast Electrical Impedance Tomography method · Diagnostic Test: Computed Tomography Pulmonary Angiography (CTPA)

Interventions

  • Diagnostic testSaline contrast Electrical Impedance Tomography method

    This study will enroll patients with clinically suspected or confirmed acute pulmonary embolism (PE) presenting with acute respiratory failure, who undergo electrical impedance tomography (EIT) with saline contrast within 24 hours before or after computed tomography pulmonary angiography (CTPA). The EIT procedure is performed as follows: 1. Breath-Hold Maneuver: (1)Spontaneous breathing patients: Supine position, instructed to hold expiration for ≥8 seconds. (2)Mechanically ventilated patients: Expiratory hold (\>8 sec) achieved via ventilator; deeper sedation will be applied when feasible to prolong breath-hold. 2. Venous Access: (1)Preferred: Central venous catheter (internal jugular or subclavian vein).(2)Alternative: Peripheral forearm vein (preferably the median cubital vein). 3. Contrast Administration:(1)Central venous route: 10 mL of 10% NaCl.(2)Peripheral venous route: 15 mL of 5% NaHCO₃.

  • Diagnostic testComputed Tomography Pulmonary Angiography (CTPA)

    Patients who meet the inclusion criteria will undergo CTPA examination using conventional clinical diagnostic methods.

06

What researchers measure

Primary outcomes

  1. The ability of proportion of dead space ventilation to diagnose PE

    The participant undergoes a saline contrast EIT examination, after which the distribution of pulmonary ventilation and perfusion will be obtained, respectively. A V-Q map will be subsequently generated. Using offline EIT data analysis tool, the proportion of lung regions with ventilation but without perfusion is calculated, representing the proportion of dead space ventilation (expressed as a percentage). Area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, Youden's index, accuracy, Kappa statistic, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR) and negative likelihood ratio (NLR) will be used to evaluate the ability of proportion of dead space ventilation to diagnose acute pulmonary embolism (PE).

    Time frame: Within 24 hours before or after the CTPA examination

Secondary outcomes

  1. The ability of proportion of V/Q matching to diagnose PE

    Following a saline contrast EIT examination, the participant's pulmonary ventilation and perfusion distributions will be obtained, allowing for the generation of a V-Q map. Using offline EIT data analysis tool, the proportion of lung regions demonstrating both ventilation and perfusion will be calculated, representing the proportion of V/Q matching (%). Area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, Youden's index, accuracy, Kappa statistic, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR) and negative likelihood ratio (NLR) will be used to evaluate the ability of proportion of V/Q matching to diagnose acute pulmonary embolism (PE).

    Time frame: Within 24 hours before or after the CTPA examination

  2. The ability of proportion of shunt to diagnose PE

    Following a saline contrast EIT examination, the participant's pulmonary ventilation and perfusion distributions will be obtained, enabling the generation of a V-Q map. Using offline EIT data analysis tool, the proportion of lung regions exhibiting perfusion without ventilation will be calculated, representing the proportion of shunt (%). Area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, Youden's index, accuracy, Kappa statistic, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR) and negative likelihood ratio (NLR) will be used to evaluate the ability of proportion of shunt to diagnose acute pulmonary embolism (PE).

    Time frame: Within 24 hours before or after the CTPA examination

  3. The ability of other indicators reflecting pulmonary ventilation and perfusion to diagnose PE

    Following a saline contrast EIT examination, the participant's pulmonary ventilation and perfusion distributions will be obtained, and a V-Q map will be subsequently generated. Using offline EIT data analysis tool, additional indices reflecting pulmonary ventilation and perfusion will be further calculated. Area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, Youden's index, accuracy, Kappa statistic, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR) and negative likelihood ratio (NLR) will be used to evaluate the ability of other indicators reflecting pulmonary ventilation and perfusion to diagnose acute pulmonary embolism (PE).

    Time frame: Within 24 hours before or after the CTPA examination

07

Study locations

1 of 1 sites recruiting
  • Department of Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality 100730, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for May 2027, 19 months after the start.

Of 135 non-industry observational studies under Pulmonary Embolism, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 119. This study's planned 19 months is below that.

Counting every sponsor, half of 160 studies reached it within 47 months; a quarter within 21 and three quarters within 105.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2025
First posted
Sep 24, 2025
StartActual
Sep 24, 2025
Primary completionEst.
May 1, 2027
CompletionEst.
Sep 15, 2027
Last update
Oct 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07190079
Responsible party
Sponsor
First posted
Sep 24, 2025
Start date
Sep 24, 2025
Primary completion
May 1, 2027 (estimated)
Completion
Sep 15, 2027 (estimated)
Last update
Oct 2, 2025

Study contacts

Huaiwu He
Contact
tjmuhhw@163.com
01069152301

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion